Previous 10 | Next 10 |
Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), simil...
Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts HAMBURG, GERMANY / ACCESSWIRE / April 10, 2023 / Evotec SE (FFSE:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced an update on the cyber attack that was...
HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and dis...
2023-04-05 21:43:43 ET Summary A reader asked me to take a look at German company Evotec, which also has a dual listing on NASDAQ under symbol EVO. His question was whether I view the company as a value trap, or as a significantly undervalued stock that I would be open to investin...
2023-03-28 13:18:08 ET Evotec SE (EVOTF) Q4 2022 Earnings Conference Call March 27, 2023 8:30 A.M. ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Matthias Ev...
2023-03-28 06:24:03 ET Bristol Myers Squibb ( NYSE: BMY ) and Evotec ( NASDAQ: EVO ) have expanded their partnership for another eight years to discover and develop neurodegenerative diseases. Germany-based Evotec will get $50M upfront, undisclosed license and...
8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PROD...
22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRY HAMBURG, GERMANY / ACCESSWIRE / March 28, 2023 / Evotec SE (Frank...
2023-03-24 05:15:54 ET Evotec ( NASDAQ: EVO ) ( OTCPK:EVOTF ) said it received a $6.6M grant from The Bill & Melinda Gates Foundation to discover and develop drugs for tuberculosis (TB). It is a second grant from the foundation to Evotec for TB drug discovery, and ...
GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC'S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 "WORLD TUBERCULOSIS DAY", ...
News, Short Squeeze, Breakout and More Instantly...
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a mul...
Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY...
Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimiz...